# Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19

> **NCT04353518** · PHASE3 · UNKNOWN · sponsor: **Cadila Pharnmaceuticals** · enrollment: 4000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Suspension of heat killed (autoclaved) Mycobacterium w
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04353518
- **Lead sponsor:** Cadila Pharnmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-30
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2020-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353518, "Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04353518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*